PL3448421T3 - Sposoby i kompozycje do zapobiegania i leczenia zrostów chirurgicznych - Google Patents

Sposoby i kompozycje do zapobiegania i leczenia zrostów chirurgicznych

Info

Publication number
PL3448421T3
PL3448421T3 PL17790649T PL17790649T PL3448421T3 PL 3448421 T3 PL3448421 T3 PL 3448421T3 PL 17790649 T PL17790649 T PL 17790649T PL 17790649 T PL17790649 T PL 17790649T PL 3448421 T3 PL3448421 T3 PL 3448421T3
Authority
PL
Poland
Prior art keywords
prevention
compositions
treatment
methods
surgical adhesions
Prior art date
Application number
PL17790649T
Other languages
English (en)
Inventor
Jonathan Tsai
Nathaniel FERNHOFF
Rahul Sinha
Yuval Rinkevich
Irving L. Weissman
Original Assignee
The Board Of Trustees Of The Leland Stanford Junior University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Board Of Trustees Of The Leland Stanford Junior University filed Critical The Board Of Trustees Of The Leland Stanford Junior University
Publication of PL3448421T3 publication Critical patent/PL3448421T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001166—Adhesion molecules, e.g. NRCAM, EpCAM or cadherins
    • A61K39/001168—Mesothelin [MSLN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Materials For Medical Uses (AREA)
PL17790649T 2016-04-29 2017-05-01 Sposoby i kompozycje do zapobiegania i leczenia zrostów chirurgicznych PL3448421T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662329666P 2016-04-29 2016-04-29
PCT/US2017/030454 WO2017190148A1 (en) 2016-04-29 2017-05-01 Methods and compositions for the prevention and treatment of surgical adhesions
EP17790649.2A EP3448421B1 (en) 2016-04-29 2017-05-01 Methods and compositions for the prevention and treatment of surgical adhesions

Publications (1)

Publication Number Publication Date
PL3448421T3 true PL3448421T3 (pl) 2022-03-28

Family

ID=60161169

Family Applications (1)

Application Number Title Priority Date Filing Date
PL17790649T PL3448421T3 (pl) 2016-04-29 2017-05-01 Sposoby i kompozycje do zapobiegania i leczenia zrostów chirurgicznych

Country Status (9)

Country Link
US (1) US10934355B2 (pl)
EP (1) EP3448421B1 (pl)
JP (1) JP7160683B2 (pl)
CA (1) CA3019841A1 (pl)
ES (1) ES2903210T3 (pl)
PL (1) PL3448421T3 (pl)
PT (1) PT3448421T (pl)
SI (1) SI3448421T1 (pl)
WO (1) WO2017190148A1 (pl)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108795867A (zh) * 2018-06-05 2018-11-13 华东理工大学 用于构建结肠癌细胞腹膜转移体外三维模型的方法
US11591390B2 (en) 2018-09-27 2023-02-28 Celgene Corporation SIRP-α binding proteins and methods of use thereof
CA3125697A1 (en) 2019-01-29 2020-08-06 Helmholtz Zentrum Munchen - Deutsches Forschungszentrum Fur Gesundheit Und Umwelt (Gmbh) Treating the causative agent in adhesiogenesis
US20200386772A1 (en) * 2019-06-05 2020-12-10 Mark D. Noar Method For Detecting Bodily Adhesions By Identifying Markers In Circulating Cells
CN115645393A (zh) * 2020-02-26 2023-01-31 上海科技大学 二氢杨梅素在抗冠状病毒中的应用
US20220233135A1 (en) * 2021-01-22 2022-07-28 Ethicon Llc Prediction of adhesions based on biomarker monitoring
US12011163B2 (en) 2021-01-22 2024-06-18 Cilag Gmbh International Prediction of tissue irregularities based on biomarker monitoring
CN113244400B (zh) * 2021-05-21 2022-12-16 华北理工大学 一种C5aRA在制备治疗和/或预防腹腔粘连的产品中的应用
WO2023079127A1 (en) * 2021-11-05 2023-05-11 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Modulators of mesothelial ecm movement

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5985660A (en) 1994-06-15 1999-11-16 Systemix, Inc. Method of identifying biological response modifiers involved in dendritic and/or lymphoid progenitor cell proliferation and/or differentiation
US5639468A (en) * 1995-06-07 1997-06-17 University Of Southern California Method for reducing or preventing post-surgical adhesion formation using manoalide and analogs thereof
ES2177075T3 (es) * 1997-10-16 2002-12-01 Tno Prevencion y tratamiento de adhesivos.
US6812220B2 (en) * 2001-08-29 2004-11-02 University Of British Columbia Pharmaceutical compositions and methods relating to fucans
DE60310383T2 (de) * 2002-01-29 2007-09-20 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw. Vorbeugung von gewebeadhäsion
US20040131600A1 (en) * 2002-03-11 2004-07-08 Diamond Michael P. Method of preventing adhesions by apoptosis of adhesion peritoneal cells
JP4224586B2 (ja) * 2004-04-28 2009-02-18 国立大学法人群馬大学 マクロファージ活性化剤並びにその製造方法及びスクリーニング方法
US20080045463A1 (en) * 2004-10-25 2008-02-21 Ajay Verma Methods For Lowering Hif-1 Mediated Gene Expression
AU2006223301B2 (en) * 2005-03-10 2010-11-04 Eisai, Inc. Anti-mesothelin antibodies
US9505867B2 (en) * 2005-05-31 2016-11-29 Ecole Polytechmique Fédérale De Lausanne Triblock copolymers for cytoplasmic delivery of gene-based drugs
JP5194207B2 (ja) * 2005-08-11 2013-05-08 エーディーイー、セラピューティックス、インコーポレーテッド 腹腔内グルタミンによる術後癒着形成の減少
US20110044937A1 (en) 2006-07-27 2011-02-24 Ottawa Health Research Institute Staged immune-response modulation in oncolytic therapy
RS53760B1 (en) * 2007-10-01 2015-06-30 Bristol-Myers Squibb Company HUMAN ANTIBODIES RELATING TO MESOTELINE AND THEIR USES
PT3056515T (pt) 2008-01-15 2019-07-19 Univ Leland Stanford Junior Métodos para manipulação da fagocitose mediada por cd47
ES2325724B1 (es) * 2008-03-11 2010-05-31 FUNDACION DE LA COMUNIDAD VALENCIANA "CENTRO DE INVESTIGACIONES PRINCIPE FELIPE" Composicion farmaceutica para inhibir el factor de transcripcion inducible por hipoxia. moduladores de procesos patologicos de angiogenesis, oncogenesis, inflamacion, apoptosis y terapia celular.
WO2010111282A1 (en) 2009-03-24 2010-09-30 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Anti-mesothelin antibodies
EP4134095A1 (en) 2009-09-15 2023-02-15 The Board of Trustees of the Leland Stanford Junior University Synergistic anti-cd47 therapy for hematologic cancers
JP2011195574A (ja) * 2010-02-25 2011-10-06 Kwansei Gakuin ビスフェノールａ誘導体を含有するｈｉｆ阻害剤
EP3766511A1 (en) * 2012-01-17 2021-01-20 The Board of Trustees of the Leland Stanford Junior University High affinity sirp-alpha reagents
AU2013232297B2 (en) * 2012-03-16 2016-01-14 The Johns Hopkins University Controlled release formulations for the delivery of HIF-1 inhibitors
CA2903773A1 (en) 2013-03-15 2014-09-25 The Board Of Trustees Of The Leland Stanford Junior University Methods for achieving therapeutically effective doses of anti-cd47 agents

Also Published As

Publication number Publication date
EP3448421A4 (en) 2019-12-25
JP2019514913A (ja) 2019-06-06
US10934355B2 (en) 2021-03-02
JP7160683B2 (ja) 2022-10-25
SI3448421T1 (sl) 2022-02-28
ES2903210T3 (es) 2022-03-31
PT3448421T (pt) 2022-01-14
US20190048077A1 (en) 2019-02-14
CA3019841A1 (en) 2017-11-02
EP3448421A1 (en) 2019-03-06
WO2017190148A1 (en) 2017-11-02
EP3448421B1 (en) 2021-11-03

Similar Documents

Publication Publication Date Title
IL268406A (en) Preparations and methods for treating hemoglobin diseases
HK1258205A1 (zh) 用於治療血紅蛋白病的組合物和方法
PT3448421T (pt) Métodos e composições para a prevenção e tratamento de aderências cirúrgicas
EP3458159A4 (en) COMPOSITIONS AND METHODS FOR PREVENTION AND TREATMENT OF MITOCHONDRIAL MYOPATHIES
ZA201900960B (en) Methods and compositions for the treatment of cancer
EP3182989A4 (en) Methods and compositions for the prevention and treatment of disease
ZA201702884B (en) Compositions and methods for the treatment and prophylaxis of surgical site infections
IL263477A (en) Compositions and methods for the treatment or prevention of oxalate-related disorders
HK1249515A1 (zh) 預防和治療聽力損失的方法和組合物
GB201611712D0 (en) Methods and compounds for the treatment or prevention of severe or persistent influenza
HK1258026A1 (zh) 預防和治療角膜混濁和瘢痕的組合物和方法
IL262508A (en) Methods and preparations for the treatment of degenerate bone
ZA201902781B (en) Compositions and methods for the treatment of xerostomia
IL266486A (en) Pharmaceutical preparations and methods for cancer treatment
ZA201808232B (en) Compositions and methods for the treatment of cancer
IL248210A0 (en) Methods and preparations for the treatment of blood vessel malformations
SG11201809811VA (en) Compositions and methods for treatment of inflammation or infection of the eye
ZA201900984B (en) Methods and compositions for the treatment of warts
EP3341006A4 (en) COMPOSITIONS AND METHODS FOR TREATING NERVE DAMAGE
EP3518951A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF ORTHOPEDIC CONDITIONS
GB201621737D0 (en) Compositions and methods of treatment
IL272147A (en) Methods and preparations for the treatment of cancer
EP3706767A4 (en) COMPOSITIONS AND METHODS OF TREATMENT OF ALLERGIES
EP3525787A4 (en) TREATMENT METHODS AND PHARMACEUTICAL COMPOSITIONS USING BCN057 OR BCN512
DK3313207T3 (en) Compositions and methods for the treatment of malnutrition